A total of 4064 people were included in the first and second phase clinical trials in China. The results of blinding revealed that the vaccine was safe after vaccination, and high titer immune response was produced after vaccination with different ages, procedures and doses. After two doses of two vaccines were inoculated according to the zero 28 day program, the positive conversion rate of comprehensive antibody reached 100%.
He disclosed that at present, the new crown inactivated vaccine is in the full sprint stage, and Sinopharm groups research and development of biological vaccine in China is the last kilometer of a long march. After the safety and protection data of phase III clinical trials are obtained, the vaccine can be put on the market after approval. In fact, at present, emergency use has been started in China, and the two inactivated vaccines of sinopharma Group China biology have been included in the scope of emergency use. At present, China biology has made preparations for large-scale production. Two new P3 production plants of Beijing Institute of biology and Wuhan Institute of biology have been completed. The production capacity may reach more than 1 billion doses next year, which can ensure safe and sufficient vaccine supply.